Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection

World Journal of Gastroenterology

Volumn 11, Issue 38, 2005, Pages 6031-6037

  Meiler, C ^a   Muhlbauer M ^a   Johann, M ^a   Hartmann, A ^a   Schnabl, B ^a   Wodarz, N ^a   Schmitz, G ^a   Scholmerich J ^a   Hellerbrand, Claus ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Alcoholic liver disease; CD14 gene; Chronic hepatitis C infection

Indexed keywords

AMINOTRANSFERASE; CD14 ANTIGEN; ENDOTOXIN; LIPOPOLYSACCHARIDE;

ADULT; ALCOHOL ABUSE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIGNAL TRANSDUCTION;

EID: 28644449170     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i38.6031     Document Type: Article

References (62)

1. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis. a critical appraisal. Hepatology 2003; 37: 493-503
2. Yamauchi M, Maezawa Y, Mizuhara Y, Ohata M, Hirakawa J, Nakajima H, Toda G. Polymorphisms in alcohol metabolizing enzyme genes and alcoholic cirrhosis in Japanese patients. a multivariate analysis. Hepatology 1995; 22: 1136-1142
3. Day CP, Bashir R, James OF, Bassendine MF, Crabb DW, Thomasson HR, Li TK, Edenberg HJ. Investigation of the role of polymorphisms at the alcohol and aldehyde dehydrogenase loci in genetic predisposition to alcohol-related end-organ damage. Hepatology 1991; 14: 798-801
4. Carr LG, Hartleroad JY, Liang Y, Mendenhall C, Moritz T, Thomasson H. Polymorphism at the P450IIE1 locus is not associated with alcoholic liver disease in Caucasian men. Alcohol Clin Exp Res 1995; 19: 182-184
5. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, Lock G, Scholmerich J, Hellerbrand C. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003; 125: 1085-1093
6. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000; 1: 386-390
7. Takamatsu M, Yamauchi M, Maezawa Y, Ohata M, Saitoh S, Toda G. Correlation of a polymorphism in the interleukin-1 receptor antagonist gene with hepatic fibrosis in Japanese alcoholics. Alcohol Clin Exp Res 1998; 22: 141-144
8. Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000; 46: 540-545
9. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26: 143-146
10. Takamatsu M, Yamauchi M, Maezawa Y, Saito S, Maeyama S, Uchikoshi T. Genetic polymorphisms of interleukin-1beta in association with the development of alcoholic liver disease in Japanese patients. Am J Gastroenterol 2000; 95: 1305-1311
11. Nanji AA, Khettry U, Sadrzadeh SM, Yamanaka T. Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. Am J Pathol 1993; 142: 367-373
12. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991; 12: 162-169
13. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994; 205: 243-247
14. Jacob AI, Goldberg PK, Bloom N, Degenshein GA, Kozinn PJ. Endotoxin and bacteria in portal blood. Gastroenterology 1977; 72: 1268-1270
15. Caradonna L, Mastronardi ML, Magrone T, Cozzolongo R, Cuppone R, Manghisi OG, Caccavo D, Pellegrino NM, Amoroso A, Jirillo E, Amati L. Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection. Curr Pharm Des 2002; 8: 995-1005
16. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, Hsu WC, Huang CC, Wang SS, Lo KJ. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995; 22: 165-172
17. Chan CC, Hwang SJ, Lee FY, Wang SS, Chang FY, Li CP, Chu CJ, Lu RH, Lee SD. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol 1997; 32: 942-946
18. Rivera CA, Bradford BU, Seabra V, Thurman RG. Role of endotoxin in the hypermetabolic state after acute ethanol exposure. Am J Physiol 1998; 275: 1252-1258
19. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-1433
20. Matsuura K, Ishida T, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S. Upregulation of mouse CD14 expression in Kupffer cells by lipopolysaccharide. J Exp Med 1994; 179: 1671-1676
21. Tracy TF Jr, Fox ES. CD14-lipopolysaccharide receptor activity in hepatic macrophages after cholestatic liver injury. Surgery 1995; 118: 371-377
22. Nanbo A, Nishimura H, Muta T, Nagasawa S. Lipopolysaccharide stimulates HepG2 human hepatoma cells in the presence of lipopolysaccharide-binding protein via CD14. Eur J Biochem 1999; 260: 183-191
23. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-Like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003; 37: 1043-1055
24. Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ. CD14 is a pattern recognition receptor. Immunity 1994; 1: 509-516
25. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995; 13: 437-457
26. Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem 1999; 274: 34116-34122
27. Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995; 181: 1743-1754
28. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A Polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20: 976-983
29. Hubacek JA, Rothe G, Pit'ha J, Skodova Z, Stanek V, Poledne R, Schmitz G. C(-260)->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999; 99: 3218-3220
30. Unkelbach K, Gardemann A, Kostrzewa M, Philipp M, Tillmanns H, Haberbosch W. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 1999; 19: 932-938
31. Obana N, Takahashi S, Kinouchi Y, Negoro K, Takagi S, Hiwatashi N, Shimosegawa T. Ulcerative colitis is associated with a promoter polymorphism of lipopolysaccharide receptor gene, CD14. Scand J Gastroenterol 2002; 37: 699-704
32. Woo JG, Assa'ad A, Heizer AB, Bernstein JA, Hershey GK. The -159 C->T polymorphism of CD14 is associated with nonatopic asthma and food allergy. J Allergy Clin Immunol 2003; 112: 438-444
33. Repo H, Anttonen K, Kilpinen SK, Palotie A, Salven P, Orpana A, Leirisalo-Repo M. CD14 and TNfa promoter polymorphisms in patients with acute arthritis. Special reference to development of chronic spondyloarthropathy. Scand J Rheumatol 2002; 31: 355-361
34. Järveläinen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 2001; 33: 1148-1153
35. Corpechot C, Poupon R. Promoter polymorphism of the CD14 endotoxin receptor gene and primary biliary cirrhosis. Hepatology 2002; 35: 242-243
36. Poullis AP, Shetty AK, Risley PD, Collinson PO, Mendall MA. Effect of the CD14 promoter polymorphism on liver function tests and its association with alcohol and obesity. Eur J Gastroenterol Hepatol 2003; 15: 1317-1322
37. Fernandez-Real JM, Broch M, Richart C, Vendrell J, Lopez-Bermejo A, Ricart W. CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab 2003; 88: 1780-1784
38. Fernandez-Real JM, Lopez-Bermejo A, Broch M, Vendrell J, Richart C, Ricart W. Circulating soluble CD14 monocyte receptor is associated with increased alanine aminotransferase. Clin Chem 2004; 50: 1456-1458
39. Oesterreicher C, Pfeffel F, Petermann D, Muller C. Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. J Hepatol 1995; 23: 396-402
40. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis. diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520
41. Janca A, Ustun TB, Early TS, Sartorius N. The ICD-10 symptom checklist: a companion to the ICD-10 classification of mental and behavioural disorders. Soc Psychiatry Psychiatr Epidemiol 1993; 28: 239-242
42. Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Rothe G, Schmitz G. The common functional C(-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes Immun 2000; 1: 405-407
43. Lichy C, Meiser H, Grond-Ginsbach C, Buggle F, Dorfer C, Grau A. Lipopolysaccharide receptor CD14 polymorphism and risk of stroke in a South-German population. J Neurol 2002; 249: 821-823
44. Hubacek J, Pitha J, Skodova Z, Poledne R. Is the CD14 receptor gene a marker for smoking dependence? Med Sci Monit 2002; 8: 172-174
45. Nevanlinna HR. The Finnish population structure. A genetic and genealogical study. Hereditas 1972; 71: 195-236
46. De la Chapelle A. Disease gene mapping in isolated human populations. the example of Finland. J Med Genet 1993; 30: 857-865
47. Yin M, Bradford BU, Wheeler MD, Uesugi T, Froh M, Goyert SM, Thurman RG. Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol 2001; 166: 4737-4742
48. Hiki N, Berger D, Mimura Y, Frick J, Dentener MA, Buurman WA, Seidelmann M, Kaminishi M, Beger HG. Release of endotoxin-binding proteins during major elective surgery: role of soluble CD14 in phagocytic activation. World J Surg 2000; 24: 499-506
49. Su GL, Rahemtulla A, Thomas P, Klein RD, Wang SC, Nanji AA. CD14 and lipopolysaccharide binding protein expression in a rat model of alcoholic liver disease. Am J Pathol 1998; 152: 841-849
50. Ballardini G, Degli ES, Bianchi FB, de Giorgi LB, Faccani A, Biolchini L, Busachi CA, Pisi E. Correlation between Ito cells and fibrogenesis in an experimental model of hepatic fibrosis. A sequential stereological study. Liver 1983; 3: 58-63
51. Knittel T, Kobold D, Piscaglia F, Saile B, Neubauer K, Mehde M, Timpl R, Ramadori G. Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers. distinct roles of (myo-) fibroblast subpopulations in hepatic tissue repair. Histochem Cell Biol 1999; 112: 387-401
52. Marra F. Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 1999; 31: 1120-1130
53. Sakuta T, Matsushita K, Yamaguchi N, Oyama T, Motani R, Koga T, Nagaoka S, Abeyama K, Maruyama I, Takada H, Torii M. Enhanced production of vascular endothelial growth factor by human monocytic cells stimulated with endotoxin through transcription factor SP-1. J Med Microbiol 2001; 50: 233-237
54. Rey Nores JE, Bensussan A, Vita N, Stelter F, Arias MA, Jones M, Lefort S, Borysiewicz LK, Ferrara P, Labeta MO. Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur J Immunol 1999; 29: 265-276
55. Arias MA, Rey Nores JE, Vita N, Stelter F, Borysiewicz LK, Ferrara P, Labeta MO. Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production. J Immunol 2000; 164: 3480-3486
56. Gut JP, Schmitt S, Bingen A, Anton M, Kirn A. Probable role of endogenous endotoxins in hepatocytolysis during murine hepatitis caused by frog virus 3. J Infect Dis 1984; 149: 621-629
57. Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A, Kalis C, Gumenscheimer M. The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 2002; 8: 319-327
58. Amati L, Cozzolongo R, Manghisi OG, Cuppone R, Pellegrino NM, Caccavo D, Jirillo E. The immune responsiveness in hepatitis C virus infected patients: effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells. Curr Pharm Des 2004; 10: 2093-2100
59. Deviere J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J, Dupont E. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 1990; 11: 628-634
60. Jarvelainen HA, Oinonen T, Lindros KO. Alcohol-induced expression of the CD14 endotoxin receptor protein in rat Kupffer cells. Alcohol Clin Exp Res 1997; 21: 1547-1551
61. Kono H, Wheeler MD, Rusyn I, Lin M, Seabra V, Rivera CA, Bradford BU, Forman DT, Thurman RG. Gender differences in early alcohol-induced liver injury: role of CD14, NF-kappaB, and TNF-alpha. Am J Physiol Gastrointest Liver Physiol 2000; 278: 652-661
62. Jarvelainen HA, Fang C, Ingelman-Sundberg M, Lindros KO. Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines. Hepatology 1999; 29: 1503-1510